Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stockwatch: Pfizer, Roche, AZ, Novo Prolong Pharmaceutical Winter

Executive Summary

Lackluster reports from Pfizer, Roche, AstraZeneca and Novo Nordisk in a second week of earnings season pervaded by below consensus 2017 guidance followed a first week punctuated by missed sales estimates. So much bad news hanging over the sector feels like a nuclear winter.

You may also be interested in...



Carrots and Stick: Biopharma At The White House

Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.

Pfizer Not Making Pricing Changes, Sees Ways To Work With Trump

Pfizer CEO Ian Read said during the company’s quarterly call that there are ‘lots of ways’ to work with the new Trump administration, his comments coming on the same day several industry leaders met with the new US president.

Novo Nordisk Shakes Up R&D Strategy To Cope With US Pricing Pressures

Increasing competition and pricing pressures in the US, have led Novo Nordisk to halve its profit growth expectations for 2017. In response, the diabetes drug developer plans to double-down on R&D efforts, expand into new therapy areas and seek external deals for early-stage assets to bulk up its pipeline.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC098175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel